Capital Strategies, L.P.Lev... Net Worth

The estimated Net Worth of Capital Strategies, L.P.Lev... is at least $36.4 Milion dollars as of 14 November 2018. Capital Lev owns over 47,768 units of Standard BioTools Inc stock worth over $36,393,968 and over the last 8 years Capital sold FLDM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Lev FLDM stock SEC Form 4 insiders trading

Capital has made over 52 trades of the Standard BioTools Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Capital bought 47,768 units of FLDM stock worth $360,648 on 14 November 2018.

The largest trade Capital's ever made was buying 250,355 units of Standard BioTools Inc stock on 1 March 2018 worth over $1,564,719. On average, Capital trades about 43,809 units every 14 days since 2016. As of 14 November 2018 Capital still owns at least 9,809,695 units of Standard BioTools Inc stock.

You can see the complete history of Capital Lev stock trades at the bottom of the page.

Insiders trading at Standard BioTools Inc

Over the last 14 years, insiders at Standard BioTools Inc have traded over $29,087,682 worth of Standard BioTools Inc stock and bought 4,143,303 units worth $24,269,186 . The most active insiders traders include Easterly Partners Llcle Par..., Capital Strategies, L.P.Lev... a Samuel D Colella. On average, Standard BioTools Inc executives and independent directors trade stock every 9 days with the average trade being worth of $72,208. The most recent stock trade was executed by Nicolas Barthelemy on 1 April 2022, trading 20,993 units of FLDM stock currently worth $78,514.

What does Standard BioTools Inc do?

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.

Complete history of Capital Lev stock trades at Standard BioTools Inc

Standard BioTools Inc executives and stock owners

Standard BioTools Inc executives and other stock owners filed with the SEC include:

• Stephen Linthwaite,
  President, Chief Executive Officer, Director
• Colin McCracken,
  Chief Commercial Officer
• Vikram Jog,
  Chief Financial Officer
• Bradley Kreger,
  Senior Vice President, Global Operations
• Nicholas Khadder,
  Senior Vice President, General Counsel, Corporate Secretary
• Colin McCracken,
  Chief Commercial Officer
• Vikram Jog,
  Chief Financial Officer
• Bradley Allen Kreger,
  Sr. VP of Global Operations
• Gerhard Burbach,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Carlos Paya,
  Independent Chairman of the Board
• Laura Clague,
  Independent Director
• Bill Colston,
  Independent Director
• Angela Peters,
  Chief HR Officer
• Mark Spearman,
  Sr. Director of Corp. Communications
• Peter DeNardo,
  Investor Relations
• Andrew Quong,
  Chief Science Officer
• Dr. Stephen R. Quake D.phil., Ph.D.,
  Co-Founder & Chairman of Advisory Board
• Venture Capital I Lpversant...,
  
• Capital Strategies, L.P.Lev...,
  
• John A Young,
  Director
• Steven Mc Phail,
  GM, PRODUCTION GENOMICS
• Mai Chan Yow,
  VP, WW Mfg & MD-Singapore
• Samuel D Colella,
  Director
• Jennifer Ling Lee,
  See Remarks
• Patrick S Jones,
  Director
• Gajus Vincent Worthington,
  President & CEO
• William Maxwell Smith,
  VP, Legal Affairs & GC
• Marc Unger,
  See Remarks
• Evan/ Fa Jones,
  Director
• Capital Strategies, L.P.Lev...,
  
• Capital Strategies, L.P.Lev...,
  
• Capital Strategies, L.P.Lev...,
  
• Ana K. Stankovic,
  Director
• Robert C Jones,
  Exec. VP, Research & Dev.
• Raymond J Whitaker,
  Director
• Kenneth J Nussbacher,
  Director
• Investments Pte Ltd.Biomedi...,
  
• Jeremy Loh,
  Director
• Partners, L.P.Euclid Sr Bio...,
  
• Easterly Partners Llcle Par...,